Source: Journal of the American Society of Nephrology. Conference titles: Annual Meeting and 1999 Renal Week. Unidade: FM
Assunto: CIRURGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHOCAIR, P. R. et al. Does plasmapheresis plus triple therapy with mycophenolate mofetil play a role in focal segmental glomerulosclerosis (FSGS) prophylaxis in renal allografts?. Journal of the American Society of Nephrology. Florida: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 07 nov. 2024. , 1999APA
Chocair, P. R., Martins, C. T., Paula, F. J., Tatsui, N. H., Mendroni, A., Araujo, P., et al. (1999). Does plasmapheresis plus triple therapy with mycophenolate mofetil play a role in focal segmental glomerulosclerosis (FSGS) prophylaxis in renal allografts? Journal of the American Society of Nephrology. Florida: Faculdade de Medicina, Universidade de São Paulo.NLM
Chocair PR, Martins CT, Paula FJ, Tatsui NH, Mendroni A, Araujo P, Duarte AJ da S, David DR, Saldanha LB, Nahas WC, Sabbaga E, Arap S, Duley J. Does plasmapheresis plus triple therapy with mycophenolate mofetil play a role in focal segmental glomerulosclerosis (FSGS) prophylaxis in renal allografts? Journal of the American Society of Nephrology. 1999 ; 10 724A res. A 3664.[citado 2024 nov. 07 ]Vancouver
Chocair PR, Martins CT, Paula FJ, Tatsui NH, Mendroni A, Araujo P, Duarte AJ da S, David DR, Saldanha LB, Nahas WC, Sabbaga E, Arap S, Duley J. Does plasmapheresis plus triple therapy with mycophenolate mofetil play a role in focal segmental glomerulosclerosis (FSGS) prophylaxis in renal allografts? Journal of the American Society of Nephrology. 1999 ; 10 724A res. A 3664.[citado 2024 nov. 07 ]
